New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2012
11:48 EDTMYGNMyriad Genetics test predicts response to platinum therapy in triple-negative BC
Myriad Genetics announced that a presentation entitled "Homologous recombination deficiency, HRD, score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer, BC," was presented on Friday, December 7, at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. The study demonstrates that Myriad's HRD test strongly predicts which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer. Triple-negative breast cancer describes breast tumors that lack estrogen receptor, progesterone receptor and HER2. This type of breast cancer tends to be more aggressive than other subtypes of breast cancer and has not been amenable to targeted therapies. The platinum class of drugs kill tumors by causing DNA damage inside the tumor and may be particularly effective against tumors that have lost their ability to repair DNA.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:45 EDTMYGNMyriad Genetics presents tumor BRACAnalysis CDx study at ESMO
Subscribe for More Information
07:24 EDTMYGNStephens to hold an investor trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use